JG
SGMO

Jain Global’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Jain Global’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-146,194
Closed -$95.9K – 1570
2025
Q1 		$95.9K Buy
146,194
+107,094
+274% +$113K ﹤0.01% 972
2024
Q4 		$39.9K Buy
+39,100
New +$71.5K ﹤0.01% 715

Other funds holding SGMO

YAG
Yorkville Advisors Global Mountainside, New Jersey $155M AUM 58.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jain Global's SGMO Position: Q2 2025 in Review

Jain Global sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2025, closing a stake of 146,194 shares — an estimated $95.9K sold.

Jain Global first reported a position in SGMO in Q4 2024 and held it in 2 quarters. The position peaked at $95.9K in Q1 2025. 114 funds tracked by Wall St. Rank hold SGMO as of Q2 2025.

  • Jain Global reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2025 after selling out during the quarter.
  • Jain Global sold 146,194 SANGAMO THERAPEUTICS INC shares in Q2 2025, an estimated $95.9K.
  • Jain Global first reported a position in SANGAMO THERAPEUTICS INC in Q4 2024 and held it in 2 quarters.
  • Jain Global's SANGAMO THERAPEUTICS INC position peaked at $95.9K in Q1 2025.
  • 114 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2025.

Based on Jain Global's 13F filing for Q2 2025, filed 14 Aug 2025.